Digital illustration symbolizing progress in ALS research.

Decoding ALS: A New Nomogram Predicts Longer Survival

Soraya Malik monogram
Soraya Malik in Health & Wellness November 2026 • 4 min read.

"Groundbreaking research identifies key factors and a novel prediction tool for amyotrophic lateral sclerosis (ALS), offering hope for personalized treatment strategies."


Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, presents a significant challenge to both patients and healthcare professionals. This progressive neurodegenerative disease, impacts nerve cells in the brain and spinal cord, leading to loss of muscle control. The course of ALS varies significantly from person to person, making it difficult to predict survival and tailor treatment plans effectively.

Better understanding of the factors that influence survival in ALS is crucial for both doctors and patients. Knowing what to expect can help patients to make informed decisions about their care and help physicians to develop better treatment options.

Now, recent research published in Aging and Disease offers hope in predicting the course of ALS. This study, conducted by researchers at West China Hospital, Sichuan University, has identified key factors associated with longer survival in ALS patients and developed a novel tool called a nomogram to predict individual outcomes.

AI Search Multiple angles on this topic

ALS Diagnosis and Its Limits

Amyotrophic lateral sclerosis (ALS), formerly known as Lou Gehrig's disease, is a neurological disorder affecting motor neurons. These nerve cells in the brain and spinal cord control voluntary muscle movement and breathing. The disease involves gradual motor-neuron loss, causing significant disability and eventual death, while treatment options remain limited. Its clinical and pathological complexity continues to make diagnosis and management challenging.

From Charcot to Prognostic Modeling

ALS was first described in the 19th century, and Jean-Martin Charcot proposed the term “amyotrophic lateral sclerosis” in 1874. The name reflected his method of connecting clinical symptoms and signs with anatomical lesions identified at autopsy. Modern accounts describe ALS etiology as multifactorial, involving complex genetic, epigenetic, and environmental interactions. A later milestone in the field was the publication of an original article titled “Prognostic Nomogram Associated with Longer Survival in Amyotrophic Lateral Sclerosis Patients.”

What Factors Predict Longer Survival in ALS?

Digital illustration symbolizing progress in ALS research.

Researchers conducted a comprehensive study involving 553 ALS patients, divided into a training set and a validation set. The goal was to identify risk factors associated with survival. Through rigorous statistical analysis, they pinpointed seven independent predictors of longer survival:

These risk factors were discovered through testing over a set period. The testing factors are:

  • Age of Onset: Later age of onset tended to correlate with longer survival.
  • Rate of Disease Progression: Slower disease progression, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), was a positive indicator.
  • Hemoglobin A1c (HbA1c) Level: Lower HbA1c levels, a marker of blood sugar control, were associated with increased survival.
  • Body Mass Index (BMI): Higher BMI appeared to offer a protective effect.
  • Creatinine Levels: Elevated creatinine levels, often linked to muscle mass, suggested better outcomes.
  • Creatine Kinase (CK): Higher levels of CK, an enzyme released from damaged muscle tissue, were also associated with longer survival.
  • Non-Invasive Positive Pressure Ventilation (NIPPV): The use of NIPPV, a form of respiratory support, significantly improved survival.
AI Search Multiple angles on this topic

Biomarkers and Prediction

Recent ALS research is examining whether routine blood biochemical biomarkers can help predict survival. One cohort analysis used survival analysis, Cox proportional-hazards modeling, and receiver operating characteristic curves to investigate these biomarkers. A systematic review of artificial intelligence and statistical methods began with 1,604 unique reports and ultimately included 15 studies on patient stratification, 28 on progression prediction, and six addressing both. Research is also expanding beyond ALS's classical motor-system focus to investigate non-motor symptoms.

The Need for External Validation

The reported ALS prognostic nomogram has an important limitation: its patients were registered at a single center. That population may not represent Chinese ALS patients as a whole. The study therefore calls for further multicenter validation in China and external validation in different ethnic populations. Until such validation is completed, the nomogram's generalizability remains uncertain.

These findings highlight the complex interplay of factors that influence the progression of ALS. While some factors, such as age of onset and disease progression, are inherent to the individual, others, like HbA1c levels and BMI, can potentially be modified through lifestyle interventions.

Hope for the Future: Personalized Treatment Strategies

This research marks a significant step forward in understanding ALS and predicting individual outcomes. The nomogram developed in this study provides a valuable tool for clinicians to assess prognosis and tailor treatment plans to each patient's unique circumstances. By integrating key factors like age of onset, disease progression, and biomarker levels, the nomogram offers a more personalized approach to ALS care, potentially leading to improved survival and quality of life.

AI Search Multiple angles on this topic

Persistent Therapeutic Challenges

ALS remains a highly heterogeneous and fatal neurodegenerative disorder, creating formidable challenges for clinical management and drug development. Since the approval of riluzole and edaravone, recent drug approvals have not eliminated the need for more effective therapies. Reviews published in 2024 continue to describe ALS as complex, with heterogeneous manifestations and a critical need for better treatments. These ongoing difficulties frame prognostic tools such as nomograms as part of a broader effort to manage an illness with substantial unmet needs.

NIPPV and the predicted chance of longer survival

  • 32In the nomogram, predicted survival beyond three years rose from 30% without NIPPV to 62% with it, a 32-percentage-point increase.[1]

Where the ALS findings are least certain

  • Because the cohort came from a single center, it may not reflect the broader Chinese ALS population or other ethnic groups.[1]
  • The study leaves unresolved whether starting NIPPV earlier helps when patients have not reached the stated respiratory-function criteria.[1]
  • The relationship between personal history and survival is not yet clear, and other patient phenotypes were not captured for assessing survival.[1]
  • Small studies have not consistently found a survival difference for patients with elevated CK, so that association is not settled across the cited evidence.[1]

The ALS survival nomogram study design

PopulationALS patients[2]
Sample size553[2]
SettingSingle center[2]
DurationMedian survival time was 3.2 years[2]
ComparisonPatients with survival longer and shorter than three years[2]
Main outcomeLonger survival[2]
Effect sizeAUC of 0.92[2]
Confidence interval95% CI: 0.88-0.96[2]
p-valueP = 0.001[2]
Times cited15[2]

How the ALS predictors compare with related evidence

A registry cohort of 638 patients likewise identified creatinine at diagnosis as an independent survival predictor, connecting the marker with fat-free muscle mass.[1]

Later reviews report mixed CK findings: some studies associated raised levels with longer survival, while another linked low CK with longer survival.[3]

Later work also notes that this model did not incorporate genetic information, while a systematic review of prognostic models questioned their usefulness because of methodological problems and lack of independent external validation.[4] [5]

What remains unresolved about ALS prognosis

  • Would the nomogram retain its predictive performance in independently collected cohorts from other centers and populations?[1] [5]
  • How might genetic information change predictions built from clinical and hematological markers?[4]
  • Do progression and survival reflect distinct outcomes, or partly overlapping features of ALS?[6]
  • Is earlier NIPPV associated with longer survival even before patients meet respiratory-function criteria?[1]

Sources

  1. Prognostic Nomogram Associated with Longer Survival in Amyotrophic Lateral Sclerosis Patients (Europe PMC, 2018)
  2. Prognostic Nomogram Associated with Longer Survival in Amyotrophic Lateral Sclerosis Patients (Aging and Disease, 2018)
  3. Routine blood biochemical biomarkers in amyotrophic lateral sclerosis: Systematic review and cohort analysis (2024)
  4. The prognostic value of systematic genetic screening in amyotrophic lateral sclerosis patients (2023)
  5. Prognostic models for amyotrophic lateral sclerosis: a systematic review. (pubmed.ncbi.nlm.nih.gov)
  6. Genome-wide DNA methylation analysis related to ALS patient progression and survival (2024)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.14336/ad.2017.1016, Alternate LINK

Title: Prognostic Nomogram Associated With Longer Survival In Amyotrophic Lateral Sclerosis Patients

Subject: Cell Biology

Journal: Aging and disease

Publisher: Aging and Disease

Authors: Qian-Qian Wei, Yongping Chen, Xueping Chen, Bei Cao, Ruwei Ou, Lingyu Zhang, Yanbing Hou, Huifang Shang

Published: 2018-01-01

Everything You Need To Know

1

What is Amyotrophic Lateral Sclerosis (ALS), and why is it important to understand?

Amyotrophic Lateral Sclerosis, or ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. This causes a loss of muscle control. Understanding ALS is significant because it varies greatly from person to person, making it difficult to predict survival rates and plan treatments. Identifying the key factors associated with survival is crucial for tailoring treatment plans.

2

What key factors were identified in the study as predictors of longer survival in ALS patients?

The study identified seven independent predictors of longer survival in ALS patients: later age of onset, slower disease progression measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), lower Hemoglobin A1c (HbA1c) levels, higher Body Mass Index (BMI), elevated creatinine levels, higher Creatine Kinase (CK) levels, and the use of Non-Invasive Positive Pressure Ventilation (NIPPV). These factors are important because they highlight the complex nature of ALS and the potential for personalized treatment strategies.

3

What is a nomogram, and what are the implications of its use in ALS care?

A nomogram is a prediction tool developed to assess prognosis and tailor treatment plans to each patient's unique circumstances. It integrates key factors, such as age of onset, disease progression, and biomarker levels, to offer a more personalized approach to ALS care. The implications of using a nomogram include the potential for improved survival rates and quality of life for ALS patients, by assisting doctors in making data-driven treatment choices.

4

What is ALSFRS-R and how does it relate to ALS?

ALS Functional Rating Scale-Revised, or ALSFRS-R, is a method to measure the rate of disease progression in ALS patients. The ALSFRS-R is important because it provides a standardized way to assess how quickly a patient's physical function is declining. Slower disease progression is a positive indicator for longer survival, making this scale a crucial part of predicting individual outcomes and informing treatment decisions. While the study only used the rate of change based on ALSFRS-R the actual score itself is a strong indicator of survival.

5

What is NIPPV, and why is it important for individuals with ALS?

Non-Invasive Positive Pressure Ventilation, known as NIPPV, is a form of respiratory support that significantly improves survival in ALS patients. NIPPV is important because ALS often weakens the muscles needed for breathing. NIPPV helps patients breathe more easily, improving their quality of life and extending their survival. The implications of NIPPV use are significant, as it provides a tangible way to manage a critical aspect of the disease and positively impact patient outcomes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.